Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Guselkumab Devices in Healthy Participants
NCT04147338Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of guselkumab in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration and Area Under the Serum Concentration-Time Curve from Time Zero to Time Infinity. Started Oct 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04147338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147338.